Summary •. Beigene · ONC+3.26%. (ONC) rockets 4.5% intraday, trading at $291.765 as of 14:23 ET • European Commission approves Tevimbra for...
5 days ago

BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments...
2 months ago

In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against other billionaire Lei Zhang's stock picks with huge upside...
2 months ago

BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs ... BeiGene is scrapping ociperlimab over a disappointing phase...
3 months ago

Share this article ... The collaboration will leverage nference's proprietary Agentic AI platform to deepen understanding of chronic lymphocytic...
3 months ago

California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent...
3 months ago

What drives BeiGene Ltd. Depositary Receipt stock price ✌️【Market Sentiment】✌️ Get in early on high-return stocks identified by our analysts...
1 day ago

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
1 month ago

On July 17, 2025, BeiGene's trading volume reached HK$234 million, marking a 72.23% increase from the previous day. The company's stock ranked 446th in...
5 days ago

BeiGene Announces First Quarter 2025 Financial Results and Business Updates · Received shareholder approval on April 28, 2025, to rename the...
2 months ago